Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00026936 · ClinicalTrials.gov registry record · Phase 2

A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning

A Phase 2 study of Neoplasm, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
140
Enrollment target
1
Study location

NCT00026936: Completed Phase 2 study of Neoplasm, sponsored by National Cancer Institute (NCI).

NCT00026936 is a Phase 2 study of Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 140 participants, below the 190-participant average among 11 other Neoplasm trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00026936, a Phase 2 study of Neoplasm, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

The utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a clinical setting will be assessed by comparing results with other fully three-dimensional programs. ROB will investigate PEREGRINE for clinical use at NCI in collaboration with Lawrence Livermore National Laboratory (LLNL).

Conditions Studied

Interventions

  • PROCEDURE Radiotherapy

Study Locations (1)

Maryland

  • National Cancer Institute (NCI) - Bethesda

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 1999-05
Est. Completion 2005-01
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00026936 record still lists

NCT00026936 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 190-participant average among 11 other Neoplasm trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Radiotherapy is the first listed.

NCT00026936 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00026936 about?

NCT00026936 is a clinical study titled "A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning". The utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a clinical setting will be assessed by comparing results with other fully three-dimensional programs. ROB will investigate PEREGRINE for clinical use at NCI in collaboration with Lawrence Livermore National Laborat...

What is the current status of trial NCT00026936?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 1999-05. Estimated completion is 2005-01.

What conditions does trial NCT00026936 study?

This clinical trial studies the following conditions: Neoplasm.

What interventions are being tested in trial NCT00026936?

The interventions under investigation include: Radiotherapy (PROCEDURE).

Who is sponsoring clinical trial NCT00026936?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00026936 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00026936's enrollment target sits among peer trials

140 5th of 11 higher than 7 of 11 other Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00026936, the US trial registry maintained by the National Library of Medicine. NCT00026936 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.